Bioterrorism Threat Shines Spotlight on Drug Manufacturing

Anthrax contamination has put pharmaceutical quality and supply issues on the front page, along with patent and pricing policies.

Related Content:

Quality SystemsRegulatory Oversight and CompliancePharmaceutical Technology-12-02-2001

A CDMO’s Role in API Quality

FDA Grants Fast Track Designation to Teva Celiac Disease Candidate

GSK, Spero Therapeutics Oral UTI Treatment Trial Stopped Early for Efficacy